Europe now has access to the X-Perps of the world's most-watched stocks, the Mag 7. $AAPL $AMZN $GOOGL $META $MSFT $NVDA $TSLA $SPCX tom Open your X-Perps account & get a €30 bonus. https://t.co/yL7HFWUu45
Top-performing stocks tracked on X
Top stocks based on 1Y%
SN
Sandisk Corporation$SNDKRising onWhy it's trendingStrong bullish X conversationBacked by solid revenue growth
Hardware, Equipment & PartsBullish sentiment
SanDisk is up 526-623% YTD and has become the top S&P 500 performer of 2026. Mizuho raised its price target from $1,825 to $2,200 citing potential for 35M TPU shipments by 2028. Bulls highlight a fundamentally restructured business model: three new long-term agreements signed in Q2 FY26 with a minimum $42B revenue commitment, 10-30% customer prepayments, and over one-third of FY27 bit shipments already locked in. The HBF (High Bandwidth Flash) thesis with the SK Hynix MOU is widely cited as underestimated. Bears flag the parabolic move, Archimedes' fresh short with a $1,200 price target, and Friday's broader semis selloff that took the stock down sharply. The dominant view is that the next leg is being set up by a memory undersupply that runs through 2027.
Proven numbers
Sandisk is the spun-out NAND and storage business from the old Western Digital, and 2026 has been the year the memory cycle finally lived up to its promise. Q1 revenue grew 251% YoY to $5.95B at a 69% operating margin and 78% gross margin — those are software-economics numbers from a memory company, driven by structural NAND/HBM tightness. Over a third of FY27 bits are already contracted, SK Hynix has publicly modeled memory shortages running into 2030, and Mizuho raised its PT to $2,200. At 51x trailing earnings and 17x sales it's not statistically cheap, but the 9.3x PEG and the locked-in 2027 supply backlog are the real reasons the stock sits in the top 1% of its 52-week range. Insider activity is normal post-run profit-taking — small officer sales at $1,479-$1,757, no signal of conviction loss.
AX
AXT, Inc.$AXTI
SemiconductorsMixed sentiment
AXT sentiment is split. Bulls cite a strong rerate thesis on InP/GaAs wafer bottlenecks for AI optics, +127% in the past three months, and Carbon RWA listing. Bears note dilution concerns from a recent secondary, insider selling earlier in the $40s, China export-control geopolitical risk, and a 'worst performing today' tape grouped with $SIVE and $XFAB.
Driven by hype
AXT Inc is the indium phosphide (InP) and gallium arsenide (GaAs) wafer manufacturer that's become a monopoly-like chokepoint for AI optical-communications materials. Q1 revenue grew 39% YoY to $33M with the InP backlog surging to over $100M — up from minimal a year ago — and management unveiled a global capacity-expansion roadmap to double InP wafer output by retrofitting existing facilities. Gross margin sits at 21%, operating margin at -14%, and the stock at 43x sales reflects how much chokepoint pricing power buyers are paying for. The cleanest tell in the bundle: the CEO's $22.3M insider sale (the largest in company history) plus director Jesse Chen's $2.1M-plus cluster of sales between June 5-10 at $86-$108 — that's executive-level conviction trim into the post-rally cooldown. China Ministry of Commerce export-approval challenges are the real near-term overhang.
AB
Abivax S.A.$ABVX
BiotechnologyMixed sentiment
Abivax sentiment is split following Phase 3 obefazimod data showing 40% placebo-adjusted clinical remission, followed by an after-hours crash from ~$175 to ~$67 on cancer-imbalance fears that bulls call statistical noise. The stock recovered toward $100, with posters citing potential big-pharma partnership or buyout talks and a possible $200+ takeout, weighed against management communication concerns.
Hinges on a big event
Abivax is the French biotech with obefazimod for ulcerative colitis — Phase 3 data just showed a remarkable 40% placebo-adjusted complete-response delta. The stock has gone up over 13x in a year on UC pipeline excitement, but a safety-table presentation issue triggered a brief sell-off and multiple class action filings. Q4 revenue was $0 (pre-revenue clinical-stage developer) with operating losses driving the -$2.10 EPS, but at a $6.66B market cap the equity is binary-event pricing on obefazimod approval. The blowout UC Phase 3 data with 40% placebo-adjusted complete-response delta is the most important positive — but the stock dropped sharply when investors initially misinterpreted a cancer/NMSC safety table, briefly trading near $70 before recovering toward $96. Acquisition rumors involving LLY, AZN, and others are circulating with potential $15-20B buyout cited. The May 11 Sofinnova Crossover I 13D/A reports a 5.5M-share passive position. Multiple class-action investigations (Schall Law, Gross Law Firm, Levi & Korsinsky, Kirby McInerney) are the legal-risk overhang on the safety-data presentation issue.
BE
Electrical Equipment & Parts
LI
Lumentum Holdings Inc.$LITERising onWhy it's trendingX chatter picking upStrong bullish X conversationBacked by solid revenue growth
Communication EquipmentWD
Western Digital Corporation$WDCHot onWhy it's trendingX chatter spiked vs its recent normBacked by solid revenue growthPrice and volume picking up
Computer HardwareUnlimited access to free plan